Key result
Levosimendan cuts cardiomyocyte apoptosis by ~19 percentage points after anoxia-reoxygenation via NCX1 inhibition.
Why the study?
Levosimendan might be cardioprotective during ischemia-reperfusion insult, but its effects and underlying mechanisms on calcium homeostasis, reverse-mode NCX activity, and apoptosis in ischemia-reperfusion injury remain unclear.
Answers are grounded in this paper and cite their sources.
Demonstrates that levosimendan reduces apoptosis and endoplasmic reticulum stress in human progenitor-derived cardiomyocytes after anoxia-reoxygenation, indicating potential cardioprotection.
Levosimendan, a known calcium sensitizer with positive inotropic and vasodilating properties, might also be cardioprotective during ischemia-reperfusion (I/R) insult. Its effects on calcium homeostasis and apoptosis in I/R injury remain unclear. Na(+)/Ca(2+) exchanger (NCX) is a critical mediator of calcium homeostasis in cardiomyocytes, with reverse-mode NCX activity responsible for intracellular calcium overload and apoptosis of cardiomyocytes during I/R. We probed effects and underlying mechanisms of levosimendan on apoptosis and NCX activity in cultured human cardiomyocyte progenitor cells (CPC)-derived cardiomyocytes undergoing anoxia-reoxygenation (A/R), simulating I/R in vivo. Administration of levosimendan decreased apoptosis of CPC-derived cardiomyocytes induced by A/R. The increase in reverse-mode NCX activity after A/R was curtailed by levosimendan, and NCX1 was translocated away from the cell membrane. Concomitantly, endoplasmic reticulum (ER) stress response induced by A/R was attenuated in CPC-derived cardiomycytes treated with NCX-targeted siRNA or levosimendan, with no synergistic effect between treatments. Results indicated levosimendan inhibited reverse-mode NCX activity to protect CPC-derived cardiomyocytes from A/R-induced ER stress and cell death.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied Simulated ischemia-reperfusion (anoxia-reoxygenation) injury in human cardiomyocyte progenitor cell-derived cardiomyocytes (n=10). Levosimendan vs. Untreated control (anoxia-reoxygenation without levosimendan) was evaluated on Apoptosis of cultured human CPC-derived cardiomyocytes after anoxia-reoxygenation (p=<0.05). Levosimendan reduced anoxia-reoxygenation-induced apoptosis in human CPC-derived cardiomyocytes from 27.6% to 8.2% (p<0.05) by inhibiting reverse-mode NCX1 activity.
Synapse has enriched 10 related papers. Consider them for comparative context: